InsiderSignalSign in

← Insider buys

SYRS

Syros Pharmaceuticals, Inc. · Healthcare

No insider bought or sold Syros Pharmaceuticals, Inc. in the last 12 months

$0Bought, 12 mo

$0Sold, 12 mo

$11KMarket cap

SYRS over the last year

Prices for SYRS aren't in yet.

SYRS after insider buys

3 months after each buy, from the first price a copier could get.

No buys have 3 months of prices yet. A record shows here at 3.

Every filing

47 insider filings since 2016, newest first

Nancy A Simonian · Director

$36K−77.0%Nov 27

Jason Haas · CFO

$29K−100.0%Nov 20

Conley Chee · President and CEO

$27K−100.0%Nov 20

Jason Haas · CFO

$161K+407.0%Sep 12

Conley Chee · President and CEO

$161K+444.0%Sep 12

Richard A Young · Director

$178K−81.0%Jul 2

David Roth · Chief Medical Officer

$52K−100.0%Apr 5

Srinivas Akkaraju · Director

$4.0M+102.0%Dec 26

David Roth · Chief Medical Officer

$31K−100.0%Dec 14

David Roth · Chief Medical Officer

$29K−100.0%Aug 2

Eric R Olson · Chief Scientific Officer

$34K−100.0%Mar 17

Richard A Young · Director

$45K−1.0%Feb 18

Richard A Young · Director

$53K−2.0%Feb 10

Richard A Young · Director

$49K−1.0%Feb 10

Richard A Young · Director

$50K−2.0%Oct 19

Richard A Young · Director

$62K−2.0%Sep 16

Eric R Olson · Chief Scientific Officer

$205K−100.0%Aug 19

Richard A Young · Director

$75K−2.0%Aug 19

Srinivas Akkaraju · Director

$2.1M−11.0%Aug 19

Richard A Young · Director

$71K−2.0%Jul 17

Srinivas Akkaraju · Director

Srinivas Akkaraju · Director

$1.7M−10.0%Jun 25

Richard A Young · Director

$52K−2.0%Jun 16

Richard A Young · Director

$55K−2.0%May 15

Mark J Alles · Director

Richard A Young · Director

$210K−6.0%Apr 17

Jeremy P. Springhorn · Chief Business Officer

$100K+133.0%Nov 12

Richard A Young · Director

$250K−6.0%Aug 19

Arch Venture Fund Vii, L.P. · 10% owner

$489K−1.0%Jul 17

Srinivas Akkaraju · Director

$4.0M+50.0%Apr 11

Arch Venture Fund Vii, L.P. · 10% owner

$1.3M−4.0%Mar 14

Arch Venture Fund Vii, L.P. · 10% owner

$1.1M−4.0%Mar 11

Srinivas Akkaraju · Director

$2.0M+25.0%Feb 2

Jeremy P. Springhorn · Chief Business Officer

Srinivas Akkaraju · Director

$992K+15.0%Dec 14

Richard A Young · Director

$72K−1.0%Aug 16

Eric R Olson · Chief Scientific Officer

$59K−100.0%Aug 8

Eric R Olson · Chief Scientific Officer

$273K−100.0%Jul 27

Richard A Young · Director

$72K−1.0%Jul 27

Amir Nashat · Director and 10% owner

$5.0M−114.0%Jul 7

Polaris Management Co. Vii, L.L.C. · 10% owner

$5.0M−114.0%Jul 7

Redmile Group, LLC · 10% owner

$5.4M−113.0%Jul 7

Flagship Ventures Fund Iv, L.P. · 10% owner

$5.0M+55.0%Jul 7

Arch Venture Fund VII LP · 10% owner

$5.0M+9.0%Jul 7

Robert Nelsen · Director and 10% owner

$5.0M+9.0%Jul 6

Aisling Capital III LP · 10% owner

$5.0M+79.0%Jul 6

James E Flynn · Possible Members of 10% Group, 10%

$5.0M+24.0%Jul 6

About Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.